$CRSP
CRISPR Therapeutics AG

2024 Q3 Form 10-Q Financial Statement

#000095017024090746 Filed on August 05, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2
Revenue $602.0K $517.0K
YoY Change -99.26%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $28.57M $71.61M
YoY Change -31.48% 12.48%
% of Gross Profit
Research & Development $82.16M $80.17M
YoY Change -9.41% -21.06%
% of Gross Profit
Depreciation & Amortization $4.800M $4.800M
YoY Change -2.04% -3.25%
% of Gross Profit
Operating Expenses $110.7M $151.8M
YoY Change -16.37% -8.14%
Operating Profit -$110.1M -$151.3M
YoY Change -16.83% 58.85%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $25.06M $26.14M
YoY Change 21.25% 42.01%
Pretax Income -$85.07M -$125.1M
YoY Change -23.87% 62.88%
Income Tax $900.0K $1.300M
% Of Pretax Income
Net Earnings -$85.94M -$126.4M
YoY Change -23.37% 62.6%
Net Earnings / Revenue -14276.08% -24450.29%
Basic Earnings Per Share -$1.01 -$1.49
Diluted Earnings Per Share -$1.01 -$1.49
COMMON SHARES
Basic Shares Outstanding 85.17M 84.92M
Diluted Shares Outstanding 85.23M 84.92M

Balance Sheet

Concept 2024 Q3 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $329.5M $672.5M
YoY Change -51.33% -61.97%
Cash & Equivalents $225.7M $484.5M
Short-Term Investments $103.8M $188.0M
Other Short-Term Assets $8.246M $8.788M
YoY Change -60.36% -59.07%
Inventory
Prepaid Expenses
Receivables $0.00 $0.00
Other Receivables $0.00 $0.00
Total Short-Term Assets $1.944B $2.010B
YoY Change 10.41% 8.11%
LONG-TERM ASSETS
Property, Plant & Equipment $138.5M $143.0M
YoY Change -11.26% -55.1%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $0.00 $11.22M
YoY Change 128.85%
Other Assets $15.89M $15.14M
YoY Change 676.31% 8.35%
Total Long-Term Assets $312.2M $329.4M
YoY Change -4.29% -2.37%
TOTAL ASSETS
Total Short-Term Assets $1.944B $2.010B
Total Long-Term Assets $312.2M $329.4M
Total Assets $2.256B $2.340B
YoY Change 8.11% 6.5%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $15.58M $9.452M
YoY Change -40.43% -65.74%
Accrued Expenses $47.20M $91.88M
YoY Change -28.91% -12.22%
Deferred Revenue $4.483M $4.759M
YoY Change 28.09%
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $89.81M $127.8M
YoY Change -19.26% -3.77%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $3.677M $3.646M
YoY Change -31.83% -98.53%
Total Long-Term Liabilities $3.677M $3.646M
YoY Change -31.83% -98.53%
TOTAL LIABILITIES
Total Short-Term Liabilities $89.81M $127.8M
Total Long-Term Liabilities $3.677M $3.646M
Total Liabilities $316.5M $358.9M
YoY Change -11.86% -5.8%
SHAREHOLDERS EQUITY
Retained Earnings -$1.329B -$1.243B
YoY Change 22.0% 27.21%
Common Stock $3.258B $3.227B
YoY Change 15.37% 15.16%
Preferred Stock
YoY Change
Treasury Stock (at cost) $62.00K $62.00K
YoY Change -1.59% -1.59%
Treasury Stock Shares
Shareholders Equity $1.940B $1.981B
YoY Change
Total Liabilities & Shareholders Equity $2.256B $2.340B
YoY Change 8.11% 6.5%

Cashflow Statement

Concept 2024 Q3 2024 Q2
OPERATING ACTIVITIES
Net Income -$85.94M -$126.4M
YoY Change -23.37% 62.6%
Depreciation, Depletion And Amortization $4.800M $4.800M
YoY Change -2.04% -3.25%
Cash From Operating Activities -$106.9M -$95.58M
YoY Change 167.95% -28.27%
INVESTING ACTIVITIES
Capital Expenditures $219.0K $707.0K
YoY Change -92.94% -86.01%
Acquisitions
YoY Change
Other Investing Activities -$161.4M -$126.2M
YoY Change -229.73% -156.85%
Cash From Investing Activities -$161.6M -$126.9M
YoY Change -233.23% -158.5%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 9.640M -466.0K
YoY Change 542.67% -102.78%
NET CHANGE
Cash From Operating Activities -106.9M -95.58M
Cash From Investing Activities -161.6M -126.9M
Cash From Financing Activities 9.640M -466.0K
Net Change In Cash -258.9M -223.0M
YoY Change -412.28% -321.97%
FREE CASH FLOW
Cash From Operating Activities -$106.9M -$95.58M
Capital Expenditures $219.0K $707.0K
Free Cash Flow -$107.1M -$96.29M
YoY Change 149.14% -30.38%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Central Index Key
EntityCentralIndexKey
0001674416
dei Amendment Flag
AmendmentFlag
false
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
00-0000000
CY2024Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-37923
dei Entity Registrant Name
EntityRegistrantName
CRISPR THERAPEUTICS AG
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
V8
dei Entity Address Address Line1
EntityAddressAddressLine1
Baarerstrasse 14
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
6300
dei Entity Address City Or Town
EntityAddressCityOrTown
Zug
dei Entity Address Country
EntityAddressCountry
CH
dei City Area Code
CityAreaCode
41 (0)41
dei Local Phone Number
LocalPhoneNumber
561 32 77
dei Security12b Title
Security12bTitle
Common Shares, nominal value CHF 0.03
dei Trading Symbol
TradingSymbol
CRSP
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
85168158
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
484472000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
389477000
CY2024Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
1517147000
CY2023Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
1304215000
CY2024Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
0
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
200000000
CY2024Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
8788000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
14386000
CY2024Q2 us-gaap Assets Current
AssetsCurrent
2010407000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
1908078000
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
143031000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
151945000
CY2024Q2 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
11216000
CY2023Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
1973000
CY2024Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
0
CY2023Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
16000
CY2024Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
11520000
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
11591000
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
148538000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
153993000
CY2024Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
15141000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1975000
CY2024Q2 us-gaap Assets
Assets
2339853000
CY2023Q4 us-gaap Assets
Assets
2229571000
CY2024Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
9452000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
38147000
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
91883000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
45335000
CY2024Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
4759000
CY2023Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
4105000
CY2024Q2 us-gaap Taxes Payable Current
TaxesPayableCurrent
454000
CY2023Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
438000
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
16451000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
15625000
CY2024Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
4824000
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
5141000
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
127823000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
108791000
CY2024Q2 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
12583000
CY2023Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
14012000
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
214852000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
223007000
CY2024Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
3646000
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
958000
CY2024Q2 us-gaap Liabilities
Liabilities
358904000
CY2023Q4 us-gaap Liabilities
Liabilities
346768000
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.03
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.03
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
132477166
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
126536183
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
85215817
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
80214694
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
85045501
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
80044378
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
2665000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
2497000
CY2024Q2 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
170316
CY2023Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
170316
CY2024Q2 us-gaap Treasury Stock Value
TreasuryStockValue
62000
CY2023Q4 us-gaap Treasury Stock Value
TreasuryStockValue
62000
CY2024Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
3223924000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
2878155000
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1242699000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-999700000
CY2024Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2879000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
1913000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
1980949000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
1882803000
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2339853000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2229571000
CY2024Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
517000
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
70000000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1021000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
170000000
CY2024Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
80165000
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
101555000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
156338000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
201490000
CY2024Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
19481000
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
19032000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
37434000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
41392000
CY2024Q2 crsp Collaboration Expense
CollaborationExpense
52131000
CY2023Q2 crsp Collaboration Expense
CollaborationExpense
44636000
crsp Collaboration Expense
CollaborationExpense
99097000
crsp Collaboration Expense
CollaborationExpense
86828000
CY2024Q2 us-gaap Operating Expenses
OperatingExpenses
151777000
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
165223000
us-gaap Operating Expenses
OperatingExpenses
292869000
us-gaap Operating Expenses
OperatingExpenses
329710000
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-151260000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-95223000
us-gaap Operating Income Loss
OperatingIncomeLoss
-291848000
us-gaap Operating Income Loss
OperatingIncomeLoss
-159710000
CY2024Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
26139000
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
18406000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
50860000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
31148000
CY2024Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
26139000
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
18406000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
50860000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
31148000
CY2024Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-125121000
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-76817000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-240988000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-128562000
CY2024Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1287000
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
923000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2011000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2243000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-126408000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-77740000
us-gaap Net Income Loss
NetIncomeLoss
-242999000
us-gaap Net Income Loss
NetIncomeLoss
-130805000
CY2024Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
2000
CY2023Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
28000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-9000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
60000
CY2024Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-1329000
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
452000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-4783000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
6679000
CY2024Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-127735000
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-77260000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-247791000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-124066000
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.49
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.98
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.92
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.66
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
84920929
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
79091061
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
83357780
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
78885168
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.49
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.98
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.92
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.66
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
84920929
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
79091061
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
83357780
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
78885168
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
1875479000
CY2023Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
5000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
4683000
CY2023Q1 crsp Stock Purchased During Period Value Employee Stock Purchase Plan
StockPurchasedDuringPeriodValueEmployeeStockPurchasePlan
660000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
20875000
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
6259000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-53065000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
1854896000
CY2023Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
4000
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
16623000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
21765000
CY2023Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
480000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-77740000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
1816028000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
1882803000
CY2024Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
277147000
CY2024Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
7000
CY2024Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
23866000
CY2024Q1 crsp Stock Purchased During Period Value Employee Stock Purchase Plan
StockPurchasedDuringPeriodValueEmployeeStockPurchasePlan
764000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
19405000
CY2024Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-3465000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-116591000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
2083936000
CY2024Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
6000
CY2024Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1070000
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
23672000
CY2024Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-1327000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-126408000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
1980949000
us-gaap Profit Loss
ProfitLoss
-242999000
us-gaap Profit Loss
ProfitLoss
-130805000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
9678000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
10012000
us-gaap Share Based Compensation
ShareBasedCompensation
43077000
us-gaap Share Based Compensation
ShareBasedCompensation
42640000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
16566000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
5620000
crsp Acquired In Process Research And Development
AcquiredInProcessResearchAndDevelopment
0
crsp Acquired In Process Research And Development
AcquiredInProcessResearchAndDevelopment
1500000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-200000000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
70000000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-5297000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-15952000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
18724000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
13637000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-775000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
0
crsp Increase Decrease In Operating Lease Assets And Liabilities
IncreaseDecreaseInOperatingLeaseAssetsAndLiabilities
-1874000
crsp Increase Decrease In Operating Lease Assets And Liabilities
IncreaseDecreaseInOperatingLeaseAssetsAndLiabilities
-1277000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-392000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-485000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
14170000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-124446000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1428000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
6614000
us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
0
us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
1500000
us-gaap Payments To Acquire Equity Securities Fv Ni
PaymentsToAcquireEquitySecuritiesFvNi
12885000
us-gaap Payments To Acquire Equity Securities Fv Ni
PaymentsToAcquireEquitySecuritiesFvNi
0
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
797509000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
452363000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
587117000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
795229000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-224705000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
334752000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
279733000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
25735000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
22169000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
305468000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
22169000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-9000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
60000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
94924000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
232535000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
401068000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
224060000
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
495992000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
456595000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
20000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1029000
crsp Equity Issuance Costs In Accounts Payable Accrued Expenses And Other Long Term Liabilities
EquityIssuanceCostsInAccountsPayableAccruedExpensesAndOtherLongTermLiabilities
3029000
crsp Equity Issuance Costs In Accounts Payable Accrued Expenses And Other Long Term Liabilities
EquityIssuanceCostsInAccountsPayableAccruedExpensesAndOtherLongTermLiabilities
293000
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
484472000
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
444796000
CY2024Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
11520000
CY2023Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
11799000
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
495992000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
456595000
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. </span><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On an ongoing basis, the Company’s management evaluates its estimates, which include, but are not limited to, revenue recognition, equity-based compensation expense and reported amounts of expenses during the period. Significant estimates in these consolidated financial statements have been made in connection with revenue recognition and equity-based compensation expense. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. Actual results may differ from those estimates or assumptions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Changes in estimates are reflected in reported results in the period in which they become known.</span></p>
CY2024Q2 us-gaap Marketable Securities
MarketableSecurities
188000000
CY2023Q4 us-gaap Marketable Securities
MarketableSecurities
197800000
CY2024Q2 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
296570000
CY2024Q2 crsp Cash Equivalents Gross Unrealized Gains Before Tax
CashEquivalentsGrossUnrealizedGainsBeforeTax
0
CY2024Q2 crsp Cash Equivalents Gross Unrealized Losses Before Tax
CashEquivalentsGrossUnrealizedLossesBeforeTax
58000
CY2024Q2 crsp Cash Equivalents Fair Value
CashEquivalentsFairValue
296512000
CY2024Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
1531204000
CY2024Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
691000
CY2024Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
3532000
CY2024Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
1528363000
CY2024Q2 crsp Cash Equivalents And Available For Sale Debt Securities Amortized Cost Basis
CashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis
1827774000
CY2024Q2 crsp Cash Equivalents And Available For Sale Debt Securities Gross Unrealized Gains Before Tax
CashEquivalentsAndAvailableForSaleDebtSecuritiesGrossUnrealizedGainsBeforeTax
691000
CY2024Q2 crsp Cash Equivalents And Available For Sale Debt Securities Gross Unrealized Losses Before Tax
CashEquivalentsAndAvailableForSaleDebtSecuritiesGrossUnrealizedLossesBeforeTax
3590000
CY2024Q2 crsp Cash Equivalents And Available For Sale Debt Securities Fair Value
CashEquivalentsAndAvailableForSaleDebtSecuritiesFairValue
1824875000
CY2023Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
191721000
CY2023Q4 crsp Cash Equivalents Gross Unrealized Gains Before Tax
CashEquivalentsGrossUnrealizedGainsBeforeTax
0
CY2023Q4 crsp Cash Equivalents Gross Unrealized Losses Before Tax
CashEquivalentsGrossUnrealizedLossesBeforeTax
0
CY2023Q4 crsp Cash Equivalents Fair Value
CashEquivalentsFairValue
191721000
CY2023Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
1304304000
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
3821000
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
1937000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
1306188000
CY2023Q4 crsp Cash Equivalents And Available For Sale Debt Securities Amortized Cost Basis
CashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis
1496025000
CY2023Q4 crsp Cash Equivalents And Available For Sale Debt Securities Gross Unrealized Gains Before Tax
CashEquivalentsAndAvailableForSaleDebtSecuritiesGrossUnrealizedGainsBeforeTax
3821000
CY2023Q4 crsp Cash Equivalents And Available For Sale Debt Securities Gross Unrealized Losses Before Tax
CashEquivalentsAndAvailableForSaleDebtSecuritiesGrossUnrealizedLossesBeforeTax
1937000
CY2023Q4 crsp Cash Equivalents And Available For Sale Debt Securities Fair Value
CashEquivalentsAndAvailableForSaleDebtSecuritiesFairValue
1497909000
CY2024Q2 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
2900000
CY2023Q4 crsp Debt Securities Available For Sale Unrealized Gain Position
DebtSecuritiesAvailableForSaleUnrealizedGainPosition
1900000
CY2024Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
995500000
CY2023Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
463500000
CY2024Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
229200000
CY2023Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
138400000
CY2024Q2 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
11200000
CY2023Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
2000000
CY2024Q2 crsp Debt Securities Available For Sale Securities Remaining Maturity Greater Than Three Year
DebtSecuritiesAvailableForSaleSecuritiesRemainingMaturityGreaterThanThreeYear
0
CY2024Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
206101000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
205378000
CY2024Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
63070000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
53433000
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
143031000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
151945000
CY2024Q2 us-gaap Depreciation
Depreciation
4800000
us-gaap Depreciation
Depreciation
9600000
CY2023Q2 us-gaap Depreciation
Depreciation
5000000
us-gaap Depreciation
Depreciation
10000000
CY2024Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
14373000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
17347000
CY2024Q2 crsp Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
19182000
CY2023Q4 crsp Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
16962000
CY2024Q2 crsp Accrued Collaboration Costs
AccruedCollaborationCosts
51455000
CY2023Q4 crsp Accrued Collaboration Costs
AccruedCollaborationCosts
2395000
CY2024Q2 crsp Accrued License Fees Current
AccruedLicenseFeesCurrent
2325000
CY2023Q4 crsp Accrued License Fees Current
AccruedLicenseFeesCurrent
3143000
CY2024Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2661000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2515000
CY2024Q2 crsp Accrued Intellectual Property Costs Current
AccruedIntellectualPropertyCostsCurrent
1379000
CY2023Q4 crsp Accrued Intellectual Property Costs Current
AccruedIntellectualPropertyCostsCurrent
1642000
CY2024Q2 crsp Accrued Property And Equipment
AccruedPropertyAndEquipment
0
CY2023Q4 crsp Accrued Property And Equipment
AccruedPropertyAndEquipment
630000
CY2024Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
508000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
701000
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
91883000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
45335000
CY2022 crsp Accounting Analysis Defer Option Specified Cost
AccountingAnalysisDeferOptionSpecifiedCost
110300000
CY2023 crsp Accounting Analysis Defer Option Specified Cost
AccountingAnalysisDeferOptionSpecifiedCost
110300000
CY2022 crsp Deferred Finance Costs Share Lending Arrangement Issuance Costs
DeferredFinanceCostsShareLendingArrangementIssuanceCosts
36100000
CY2023 crsp Deferred Finance Costs Share Lending Arrangement Issuance Costs
DeferredFinanceCostsShareLendingArrangementIssuanceCosts
80900000
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.03
CY2024Q2 us-gaap Deferred Compensation Arrangement With Individual Common Stock Reserved For Future Issuance
DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance
20925932
CY2024Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
280000000
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
71.5
CY2024Q1 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
279000000
CY2024Q1 crsp Stamp Taxes Due On Issuance Of Common Stock
StampTaxesDueOnIssuanceOfCommonStock
2800000
CY2024Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
23672000
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
21765000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
43077000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
42640000
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7204372
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
55.05
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1056224
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
68.76
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
677561
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
37.92
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
278612
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
72.96
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7304423
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
57.94
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
4714519
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
56.5
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
7304423
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
57.94
CY2024Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9315656
CY2023Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8887196
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9315656
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8887196
CY2024Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1300000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2000000
CY2024Q2 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.011
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.009
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
900000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2200000
CY2023Q2 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.012
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.017

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
0000950170-24-090746-index-headers.html Edgar Link pending
0000950170-24-090746-index.html Edgar Link pending
0000950170-24-090746.txt Edgar Link pending
0000950170-24-090746-xbrl.zip Edgar Link pending
crsp-20240630.htm Edgar Link pending
crsp-20240630.xsd Edgar Link pending
crsp-ex10_2.htm Edgar Link pending
crsp-ex31_1.htm Edgar Link pending
crsp-ex31_2.htm Edgar Link pending
crsp-ex32_1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
crsp-20240630_htm.xml Edgar Link completed
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending